Caplin Point Laboratories (NSE:CAPLIPOINT) Owner Earnings per Share (TTM): 66.07 (As of Mar. 2026) — 81% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CAPLIPOINT Caplin Point Laboratories Ltd NSE:CAPLIPOINT
91 GF Score
Price ₹2,623.80
GF Value ₹2,114.50
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caplin Point Laboratories Owner Earnings per Share (TTM)?

Caplin Point Laboratories NSE:CAPLIPOINT +1.93% 91 Owner Earnings per Share (TTM) is 66.07 as of Mar. 2026, which is 81% above its 10-year median of 36.60. GuruFocus rates NSE:CAPLIPOINT with a GF Score™ of 91/100 and a GF Value™ of ₹2,114.50 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 463 Drug Manufacturers companies, Caplin Point Laboratories ranks worse than 66.74% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Caplin Point Laboratories's Owner Earnings per Share (TTM) ended in Mar. 2026 was ₹66.07. It's Price-to-Owner-Earnings ratio for today is 39.71.


The historical rank and industry rank for Caplin Point Laboratories's Owner Earnings per Share (TTM) or its related term are showing as below:

NSE:CAPLIPOINT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.75   Med: 36.6   Max: 94.52
Current: 38.96


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Caplin Point Laboratories was 94.52. The lowest was 12.75. And the median was 36.60.


NSE:CAPLIPOINT's Price-to-Owner-Earnings is ranked worse than
66.74% of 463 companies
in the Drug Manufacturers industry
Industry Median: 23.87 vs NSE:CAPLIPOINT: 38.96

Caplin Point Laboratories's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was ₹22.31. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹84.10. It's PE Ratio (TTM) ratio for today is 31.20.

Caplin Point Laboratories's EPS without NRI for the three months ended in Mar. 2026 was ₹22.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹84.10. It's PE Ratio without NRI ratio for today is 31.20.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Caplin Point Laboratories Owner Earnings per Share (TTM) Related Terms


Caplin Point Laboratories Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Caplin Point Laboratories's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caplin Point Laboratories Owner Earnings per Share (TTM) Chart

Caplin Point Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.34 35.85 41.76 53.45 66.08

Caplin Point Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.45 0.00 0.00 0.00 66.08

NSE:CAPLIPOINT vs ZTS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caplin Point Laboratories Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's Price-to-Owner-Earnings falls into.


NSE:CAPLIPOINT
91GF Score
Caplin Point Laboratories Ltd NSE:CAPLIPOINT
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caplin Point Laboratories Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Caplin Point Laboratories's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 6,412
Depreciation, Depletion and Amortization 728
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 1,011
Change In Working Capital -1,090
Shares Outstanding (Diluted Average) 76

1. Start with "Net Income" from income statement. Caplin Point Laboratories's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹6,412 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Caplin Point Laboratories's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was ₹728 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Caplin Point Laboratories's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = ₹1,011 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Caplin Point Laboratories's 5-Year Average Maintenance Capital Expenditure = ₹1,011 Mil

5. "Change In Working Capital" is from cashflow statement. Caplin Point Laboratories's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-1,090 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Caplin Point Laboratories's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 76.238 Mil.

Caplin Point Laboratories's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 6412.4 +727.7+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-1011.334+-1089.9)/76.238
=66.07

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=2623.80/66.07
=39.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 66.07 mean?
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Owner Earnings per Share (TTM) of 66.07 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Caplin Point Laboratories. This is 81% above median its historical median of 36.60. Over the past decade, Caplin Point Laboratories' Owner Earnings per Share (TTM) has ranged from 12.75 to 94.52. According to the industry distribution chart, Caplin Point Laboratories ranks #309 out of 463 companies in the Drug Manufacturers industry, placing it in the top 66.7%.
Is Caplin Point Laboratories' Owner Earnings per Share (TTM) too high?
Caplin Point Laboratories' current Owner Earnings per Share (TTM) of 66.07 is 81% above median its 10-year median of 36.60. Over the past 10 years, this metric has ranged from a low of 12.75 to a high of 94.52. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.87. Caplin Point Laboratories' value of 66.07 is 176.8% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #309 out of 463 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Caplin Point Laboratories has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Owner Earnings per Share (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #309 out of 463 companies for Owner Earnings per Share (TTM). This places Caplin Point Laboratories in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.87. Caplin Point Laboratories' value of 66.07 is 176.8% above this benchmark. Historically, Caplin Point Laboratories' own Owner Earnings per Share (TTM) has ranged from 12.75 to 94.52 over the past decade. While the company's 10-year median is 36.60 vs. the industry median of 23.87, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.87, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current Owner Earnings per Share (TTM) of 66.07 is 176.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Caplin Point Laboratories. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current Owner Earnings per Share (TTM) is 66.07, which is 81% above median its own 10-year median of 36.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,114.50, compared to a current price of ₹2,623.80 — trading 24.1% above its estimated fair value. The current Owner Earnings per Share (TTM) is 66.07, which is 81% above median its 10-year median of 36.60 and 176.8% above the Drug Manufacturers industry median of 23.87. Caplin Point Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Owner Earnings per Share (TTM) is 66.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?

Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued. The current stock price of ₹2,623.80 is trading 24.1% above its estimated GF Value™ of ₹2,114.50. GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:CAPLIPOINT:

  • Owner Earnings per Share (TTM): 66.07 (81% above median its 10-year median of 36.60)
  • GF Value™: ₹2,114.50 vs. price of ₹2,623.80 (24.1% above fair value)
  • GF Score™: 91/100 with 5 warning signs
  • Industry Position: 176.8% above the Drug Manufacturers median (#309 of 463)

No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Caplin Point Laboratories Business Description

Other Exchanges 524742:India
Address Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
91GF Score

Get the complete analysis for NSE:CAPLIPOINT

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,623.80
Price
₹2,114.50
GF Value